Project Grant R01AI186847
Award Date
8/5/24
Completion Date
6/30/29
Dollars Obligated
$1.3M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Gainesville, FL 32611, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support scientific research on the pharmacokinetics and pharmacogenomics of dolutegravir-based antiretroviral therapy in young people living with HIV in Ghana. The key objectives are to determine rates of dolutegravir resistance, assess pharmacokinetic and pharmacogenomic variability, and understand the influence on...
This federal Project Grant award, totaling $1,564,570.00, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds a research project to identify drivers of genital inflammation and HIV acquisition in women living in sub-Saharan Africa.
The key products and services to be delivered through this 5-year grant include:
Preprocessing and transforming demographic, clinical, behavioral,...
This $1,326,688 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to unravel the impact of in-utero HIV exposure on hematopoietic stem cells (HSCs) and immune dysfunction in HIV-exposed, uninfected (HEU) infants born to antiretroviral-treated mothers. The research aims to investigate physiological and molecular changes in HSC self-renewal and differentiation in HEU infants, assess...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA Program 93.855 - Allergy and Infectious Diseases Research - totals $718,758 over the period of September 1, 2024 to August 31, 2025. The grant aims to explore the use of an IL-21-IgFc fusion protein as a host-directed immunotherapy to enhance immunity in individuals with tuberculosis (TB)/HIV co-infection. Specifically, the research will investigate whether supplementing...
This federal Project Grant award, valued at $645,900 and issued by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research), will support a comprehensive and prospective investigation of the extent and impact of transmitted and acquired HIV drug resistance in a large HIV care program in Kenya.
The award will enable the primary grantee, The Miriam Hospital Lifespan Division, to enroll and follow 1,840 Kenyan persons living with HIV...
This $1,041,232 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to better understand the barriers to HIV eradication in lymph nodes and the gut. The primary awardee, The General Hospital Corporation (Massachusetts General Hospital), will use advanced imaging and omics technologies to characterize the cellular and molecular processes that impede immune-mediated elimination of HIV in...
This $1,617,200 federal Project Grant award, issued by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research program), supports research to investigate the immune microenvironments that impact HIV persistence and expression during antiretroviral therapy. The research aims to determine the location, phenotype, and microenvironment of HIV RNA-expressing cells in secondary lymphoid tissues of people with HIV on prolonged antiretroviral...
This $113,400 Project Grant award from the National Institutes of Health's Fogarty International Center (CFDA 93.989 International Research and Research Training) supports an HIV cure research program in Botswana conducted by the Botswana Harvard Health Partnership. The key objectives are to: 1) identify adolescents with low HIV reservoirs potentially suitable for analytical treatment interruption studies, 2) evaluate reservoir changes over time in this cohort, and 3) identify biomarkers...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports scientific research to understand HIV persistence and HIV-induced immune activation despite effective antiretroviral therapy (ART). The $872,684 award, with a performance period from June 2024 to May 2029, will utilize single-cell multi-omic approaches to profile the rare and heterogeneous HIV-infected cells and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support research to improve HIV testing among children under five in rural Uganda. The $431,712 award to the Regents of the University of California, San Francisco (UCSF) has an anticipated completion date of July 31, 2026.
The project aims to adapt UCSF's previous successful program of partnering with traditional healers to facilitate HIV...